{"id":312801,"date":"2025-02-14T17:34:00","date_gmt":"2025-02-14T17:34:00","guid":{"rendered":"http:\/\/www.cheln.com\/index.php\/2025\/02\/14\/9747ba893c90e58b7f3bbefd6de24ca0"},"modified":"2025-02-14T17:34:00","modified_gmt":"2025-02-14T17:34:00","slug":"9747ba893c90e58b7f3bbefd6de24ca0","status":"publish","type":"post","link":"http:\/\/www.cheln.com\/index.php\/2025\/02\/14\/9747ba893c90e58b7f3bbefd6de24ca0\/","title":{"rendered":"Galderma\u300fs Nemluvio\u00ae (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
"},"content":{"rendered":"
\"\u9996\u5716\" ZUG, Switzerland–(BUSINESS WIRE)–Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodulari…<\/div>\n